2019 Q1 Form 10-Q Financial Statement
#000156459019017467 Filed on May 09, 2019
Income Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| Revenue | $28.22M | $38.02M |
| YoY Change | -25.77% | 53.74% |
| Cost Of Revenue | $5.440M | $6.646M |
| YoY Change | -18.15% | 8.4% |
| Gross Profit | $22.78M | $31.37M |
| YoY Change | -27.38% | 68.69% |
| Gross Profit Margin | 80.72% | 82.52% |
| Selling, General & Admin | $25.00M | $18.70M |
| YoY Change | 33.69% | 55.83% |
| % of Gross Profit | 109.74% | 59.61% |
| Research & Development | $118.5M | $99.42M |
| YoY Change | 19.15% | 62.84% |
| % of Gross Profit | 519.99% | 316.92% |
| Depreciation & Amortization | $3.100M | $2.500M |
| YoY Change | 24.0% | -37.5% |
| % of Gross Profit | 13.61% | 7.97% |
| Operating Expenses | $118.5M | $99.42M |
| YoY Change | 19.15% | 62.84% |
| Operating Profit | -$120.7M | -$86.74M |
| YoY Change | 39.14% | 59.34% |
| Interest Expense | $5.226M | $5.340M |
| YoY Change | -2.13% | -1.15% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $1.192M | -$8.788M |
| YoY Change | -113.56% | -5.46% |
| Pretax Income | -$119.5M | -$95.53M |
| YoY Change | 25.09% | 49.89% |
| Income Tax | $137.0K | $265.0K |
| % Of Pretax Income | ||
| Net Earnings | -$119.6M | -$95.79M |
| YoY Change | 24.89% | 49.99% |
| Net Earnings / Revenue | -423.9% | -251.96% |
| Basic Earnings Per Share | -$0.69 | -$0.60 |
| Diluted Earnings Per Share | -$0.69 | -$0.60 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 174.1M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $1.389B | $296.7M |
| YoY Change | 368.05% | -17.24% |
| Cash & Equivalents | $106.8M | $34.81M |
| Short-Term Investments | $1.282B | $261.9M |
| Other Short-Term Assets | $46.80M | $13.10M |
| YoY Change | 257.25% | 65.82% |
| Inventory | $11.80M | $10.70M |
| Prepaid Expenses | ||
| Receivables | $42.90M | $15.60M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $1.490B | $336.0M |
| YoY Change | 343.48% | -11.81% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $141.6M | $46.30M |
| YoY Change | 205.83% | -30.52% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $455.9M | $37.20M |
| YoY Change | 1125.54% | 962.86% |
| Other Assets | $2.400M | $800.0K |
| YoY Change | 200.0% | -7.51% |
| Total Long-Term Assets | $676.4M | $160.8M |
| YoY Change | 320.65% | 9.03% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $1.490B | $336.0M |
| Total Long-Term Assets | $676.4M | $160.8M |
| Total Assets | $2.167B | $496.8M |
| YoY Change | 336.09% | -6.0% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $11.00M | $11.40M |
| YoY Change | -3.51% | 64.01% |
| Accrued Expenses | $77.60M | $49.70M |
| YoY Change | 56.14% | 67.91% |
| Deferred Revenue | $11.09M | |
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $99.70M | $80.70M |
| YoY Change | 23.54% | 2.78% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $247.4M | $245.6M |
| YoY Change | 0.73% | 0.04% |
| Other Long-Term Liabilities | $185.9M | $112.2M |
| YoY Change | 65.69% | 2625.95% |
| Total Long-Term Liabilities | $433.3M | $357.8M |
| YoY Change | 21.1% | 8592.91% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $99.70M | $80.70M |
| Total Long-Term Liabilities | $433.3M | $357.8M |
| Total Liabilities | $533.0M | $438.5M |
| YoY Change | 21.55% | -9.35% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $1.634B | $58.28M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $2.167B | $496.8M |
| YoY Change | 336.09% | -6.0% |
Cashflow Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$119.6M | -$95.79M |
| YoY Change | 24.89% | 49.99% |
| Depreciation, Depletion And Amortization | $3.100M | $2.500M |
| YoY Change | 24.0% | -37.5% |
| Cash From Operating Activities | -$80.90M | -$52.47M |
| YoY Change | 54.19% | 51.64% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $5.648M | $985.0K |
| YoY Change | 473.4% | -75.91% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$6.500M | $49.20M |
| YoY Change | -113.21% | -646.67% |
| Cash From Investing Activities | -$12.14M | $48.21M |
| YoY Change | -125.18% | -468.02% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | $4.894M | 34.35M |
| YoY Change | -85.75% | 206.71% |
| NET CHANGE | ||
| Cash From Operating Activities | -$80.90M | -52.47M |
| Cash From Investing Activities | -$12.14M | 48.21M |
| Cash From Financing Activities | $4.894M | 34.35M |
| Net Change In Cash | -$88.15M | 30.04M |
| YoY Change | -393.42% | -182.31% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$80.90M | -$52.47M |
| Capital Expenditures | $5.648M | $985.0K |
| Free Cash Flow | -$86.54M | -$53.45M |
| YoY Change | 61.91% | 38.16% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
83475000 | |
| CY2018Q4 | us-gaap |
Goodwill
Goodwill
|
76501000 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
4244000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
2150172000 | |
| CY2018Q4 | nktr |
Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
|
14700000 | |
| CY2019Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
14624000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
9580000 | |
| CY2019Q1 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
4090000 | |
| CY2018Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
4198000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1649000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
11092000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
13892000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
95024000 | |
| CY2018Q4 | nktr |
Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
|
82911000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
9340000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
10744000 | |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
28222000 | |
| CY2018Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
38018000 | |
| CY2019Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
5440000 | |
| CY2018Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
6646000 | |
| CY2019Q1 | us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
us-gaap:ProductMember | |
| CY2018Q1 | us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
us-gaap:ProductMember | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
118463000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
25006000 | |
| CY2019Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
148909000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-120687000 | |
| CY2019Q1 | us-gaap |
Interest Expense
InterestExpense
|
5226000 | |
| CY2019Q1 | nktr |
Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
|
6065000 | |
| CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
12483000 | |
| CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1192000 | |
| CY2019Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-119495000 | |
| CY2019Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-983000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-118512000 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.68 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
173859000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-114912000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
87828000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
34406000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
19949000 | |
| CY2018Q1 | us-gaap |
Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
|
12577000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-685000 | |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
58283000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
5463000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
25385000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-118512000 | |
| CY2018Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-95792000 | |
| CY2019Q1 | nktr |
Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
|
8230000 | |
| CY2018Q1 | nktr |
Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
|
6920000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
25385000 | |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
19949000 | |
| CY2019Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
3077000 | |
| CY2018Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
2541000 | |
| CY2019Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
4303000 | |
| CY2018Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
370000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-319000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-151000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
397000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-51000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-4209000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-1853000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
5156000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
6492000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
8434000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
6867000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
774000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
10826000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-4204000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-3678000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-80895000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-52466000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
368739000 | |
| CY2019Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
362249000 | |
| CY2018Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
11963000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
5648000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
985000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-12138000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
48210000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
4894000 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
34352000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4894000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
34352000 | |
| CY2019Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-14000 | |
| CY2018Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-53000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-88153000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
30043000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
194905000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
4762000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
106752000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
34805000 | |
| CY2019Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
4805000 | |
| CY2018Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
4952000 | |
| CY2019Q1 | nktr |
Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
|
13956000 | |
| CY2019Q1 | nktr |
Lessee Operating Lease Liability Payments Due After Year Six
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix
|
78233000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
146901000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
44681000 | |
| CY2019Q1 | nktr |
Lessee Operating Lease Liability Tenant Improvement Reimbursements
LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
|
5547000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
96673000 | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P10Y9M18D | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.065 | |
| nktr |
Estimated Annual Interest Rate Over Life Of Royalty Liability
EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
|
0.17 | ||
| CY2017Q4 | nktr |
Estimated Annual Interest Rate Over Life Of Royalty Liability
EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
|
0.176 | |
| CY2017Q4 | nktr |
Prospective Interest Rate Percentage
ProspectiveInterestRatePercentage
|
0.21 | |
| CY2018Q4 | nktr |
Estimated Annual Interest Rate Over Life Of Royalty Liability
EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
|
0.187 | |
| CY2018Q4 | nktr |
Prospective Interest Rate Percentage
ProspectiveInterestRatePercentage
|
0.29 | |
| CY2019Q1 | nktr |
License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
|
4204000 | |
| CY2018Q1 | nktr |
License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
|
13727000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
19600000 | |
| CY2018Q1 | us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
28000000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
24636000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
4204000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
20432000 | |
| CY2019Q1 | nktr |
Potential Development And Regulatory Milestones
PotentialDevelopmentAndRegulatoryMilestones
|
1700000000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
|
698000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
|
2854816 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5854000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
9937000 | |
| CY2019Q1 | nktr |
Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
|
21384000 | |
| CY2018Q4 | nktr |
Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
|
23841000 | |
| CY2019Q1 | nktr |
Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
|
17496000 | |
| CY2019Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to estimated selling prices of performance obligations and estimates of variable consideration in collaboration agreements, estimated royalty revenue, other estimates required for revenue recognition as described further below, the net realizable value of inventory, the impairment of investments, goodwill and long-lived assets, contingencies, accrued clinical trial, contract manufacturing and other expenses, estimated non-cash royalty revenue and non-cash interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, estimates are assessed each period and updated to reflect current information and any changes in estimates will generally be reflected in the period first identified.</p> | |
| CY2019Q1 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders’ equity. </p> | |
| CY2019Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Concentrations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe <font style="color:#000000;">and with whom we have multi-year arrangements</font>. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of March 31, 2019, our accounts receivable includes $14.5 million from contracts with customers and $28.4 million for net expense reimbursements from our collaboration partner. As of December 31, 2018, our accounts receivable includes $24.2 million from contracts with customers and $19.0 million for expense reimbursements from our collaboration partner. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</p> | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
12671000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
13087000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
13515000 | |
| CY2019Q1 | us-gaap |
Debt Instrument Maturity Date
DebtInstrumentMaturityDate
|
2020-10-05 | |
| CY2019Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2019Q1 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
14500000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
24200000 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
83500000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
96200000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
1100000 | |
| CY2018Q4 | nktr |
Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
|
1918239000 | |
| CY2019Q1 | nktr |
Debt Investment Maximum Maturity Period
DebtInvestmentMaximumMaturityPeriod
|
Two years or less | |
| CY2019Q1 | nktr |
Debt Investment Maturity Date Description
DebtInvestmentMaturityDateDescription
|
One year or less | |
| CY2019Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
0 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1789213000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1800011000 | |
| CY2019Q1 | us-gaap |
Cash
Cash
|
6389000 | |
| CY2018Q4 | us-gaap |
Cash
Cash
|
5812000 | |
| CY2018Q1 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2018Q1 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
1688000 | |
| CY2018Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
1846000 | |
| CY2019Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
8932000 | |
| CY2018Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
6403000 | |
| CY2019Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
1158000 | |
| CY2018Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
3132000 | |
| CY2019Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2957000 | |
| CY2018Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1838000 | |
| CY2019Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
1273000 | |
| CY2018Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
1093000 | |
| CY2019Q1 | us-gaap |
Lease Cost
LeaseCost
|
4230000 | |
| CY2018Q1 | us-gaap |
Lease Cost
LeaseCost
|
2931000 | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1800000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
5749000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
9690000 |
